The clinical evaluation of a new topical corticosteroid, clobetasol propionate.

Abstract

A new topically active corticosteroid, clobetasol propionate, has been investigated in the laboratory and in dermatological clinics to determine the best formulation for clinical use. Clinical trials involving 1150 patients were undertaken. In patients with bilateral psoriasis or eczema, clobetasol propionate, at a strength of 0.05%, was compared with betamethasone 17‐valerate ointment and cream, fluclorolone acewnidc ointment and cream and fluocinonide (FAPG). The new steroid was shown to be effective therapeutically, especially in psoriasis. Each comparison in the trial was analysed independently and the following statistically significant differences were demonstrated.